Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors


Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors


Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy with or without radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery.


This phase II trial is studying how well combination chemotherapy works in treating patients with stage III or stage IV malignant peripheral nerve sheath tumors.

Study Status: Recruiting

Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100

Condition Intervention Phase
Neurofibromatosis Type 1 (nf1)
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: filgrastim
Drug: ifosfamide
Procedure: conventional surgery
Procedure: radiation therapy
Phase 2

Verified by Sarcoma Alliance for Research through Collaboration June, 2007

Sponsored by: Sarcoma Alliance for Research through Collaboration
Information provided by: National Cancer Institute (NCI) identifier: NCT00304083

Study Type: Interventional

Study Design: Treatment, Open Label

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Denise Reinke, MS, NP., Principal Investigator
Brigitte C. Widemann, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site